PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “OSTEOARTHROPATHY, HYPERTROPHIC PULMONARY”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1975

Radionuclide bone images in hypertrophic pulmonary osteoarthropathy.

Hypertrophic Pulmonary Osteoarthropathy (HPO) can be differentiated from osseous metastasis on conventional bone images using technetium 99m radiopharmaceuticals. Periosteal new bone formation appears as symmetric circumferential deposition of radionuclide in the diaphyseal cortex of tubular bones. In contrast, asymmetrical deposits in the medullary canal are indicative of metastatic disease. The etiologies of hypertrophic osteoarthropathy are discussed.

Bone Neoplasms↗
PubMed1997

The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA).

BACKGROUND: Hypertrophic pulmonary osteoarthropathy (HPOA) secondary to bronchogenic carcinoma can be associated with severe, disabling pain which is not always responsive to conventional treatment. AIM: To report on the use of pamidronate to control resistant pain in HPOA in three cases. METHODS: A retrospective review of reported pain, chest X-ray and radionuclide bone scans was made. RESULTS: Pain relief was achieved in all three cases together with reduced radiolabel uptake in two cases. CONCLUSIONS: Pamidronate appears to be an effective therapy for HPOA. Further investigation is warranted.

Adenocarcinoma↗
PubMed1987

Hypertrophic pulmonary osteoarthropathy and breast cancer.

Hypertrophic pulmonary osteoarthropathy is an uncommon, poorly understood syndrome usually seen with bronchogenic carcinomas, and rarely with tumors metastatic to the lungs or mediastinum. In a review of the literature, we have found only 140 cases associated with nonbronchogenic intrathoracic tumors. We have reported a case associated with metastatic breast carcinoma in which surgical resection led to rapid disappearance of the syndrome and prolonged palliation for the patient.

Adenocarcinoma↗
PubMed2002

Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis.

Hypertrophic pulmonary osteoarthropathy (HPOA) may complicate the advanced lung disease that is associated with cystic fibrosis, resulting in severe joint pain and early-morning stiffness. Symptoms are usually controlled with the administration of nonsteroidal anti-inflammatory drugs, physiotherapy, and, on occasions, oral corticosteroids. This report describes a case of refractory HPOA with complete remission following the administration of IV pamidronate, which is a potent inhibitor of osteoclastic bone resorption. Symptom relief resulted for up to 3 months, but repeated courses of pamidronate have been required to maintain symptom control.

Adult↗
PubMed1984

Hypertrophic pulmonary osteoarthropathy heralding relapse of lymphoepithelioma.

Hypertrophic pulmonary osteoarthropathy is an uncommon paraneoplastic syndrome occasionally associated with nasopharyngeal lymphoepitheliomas. We treated two patients with previously diagnosed lymphoepitheliomas in whom hypertrophic pulmonary osteoarthropathy preceded the recognition of pulmonary metastases. Both patients' disabling arthritic syndromes resolved with effective therapy directed at their neoplasms.

Adolescent↗
PubMed1975

Hypertrophic Pulmonary Osteoarthropathy in Pulmonary Metastases.

Hypertrophic pulmonary osteoarthropathy is most commonly encountered in association with bronchogenic carcinoma and tumors of the pleura. Its association with pulmonary metastases from extrathoracic neoplasms is rare, with only 44 documented cases in the literature. Three additional cases are reported. Nearly half of the reported cases have been sarcomas, mainly of bone and soft tissues; among the rest are tumors of the nasopharynx and uterus and cervix. It has recently been noted that symptoms can be dramatically relieved by intrathoracic or cervical vagotomy.

Adenocarcinoma↗
PubMed1985

Hypertrophic pulmonary osteoarthropathy in four patients with interstitial pulmonary disease.

The association between digital clubbing and idiopathic pulmonary fibrosis has been well established; however, the simultaneous occurrence of hypertrophic pulmonary osteoarthropathy and interstitial fibrosis, in the absence of neoplastic disease, has only been described in two case reports and was not mentioned in any of 336 patients described in several recent reviews. Among 70 patients referred for investigation of pulmonary infiltrates, four were found to have hypertrophic pulmonary osteoarthropathy associated with interstitial pulmonary disease, in the absence of malignant disease. We conclude that the use of bone scans and roentgenographic examination of the extremities may draw attention to an association between hypertrophic pulmonary osteoarthropathy and idiopathic pulmonary fibrosis.

Aged↗
PubMed1985

Indomethacin therapy for hypertrophic pulmonary osteoarthropathy in patients with bronchogenic carcinoma.

Hypertrophic pulmonary osteoarthropathy (HPO) is a disabling complication of lung cancer often requiring thoracotomy with vagotomy for control of pain. This condition was confirmed by scintigraphy in six consecutive patients with biopsy-proved lung cancer. All had characteristic bone and joint pain unresponsive to a variety of analgesics. Treatment with indomethacin gave dramatic relief of pain within 72 hours in all six. Consideration should be given to instituting a controlled trial to establish the efficacy of indomethacin for the treatment of HPO.

Adult↗
PubMed1980

Effect of atropine sulfate in pulmonary hypertrophic osteoarthropathy.

A 49-year-old patient with pulmonary hypertrophic osteoarthropathy was treated with 0.4 mg of atropine sulfate every 4 hours for 14 days. A good clinical response was obtained as measured by handgrip strength, range of motion, and quantitative thermography. Chemical vagotomy supports the hypothesis of the vagal reflex as the pathophysiological mechanism in pulmonary hypertrophic osteoarthropathy.

Atropine↗
PubMedDate not supplied

Hypertrophic pulmonary osteoarthropathy inactivated by antitumor chemotherapy.

A case of hypertrophic pulmonary osteoarthropathy (HPO) associated with carcinoma of the lung is reported. HPO in this patient was documented by Tc-99m methylene diphosphonate scans over a period of seven months. He was treated solely by antitumor chemotherapy, and his HPO was inactivated in three months. Whereas most reports refer to surgery, vagotomy, or radiotherapy for the treatment of lung carcinoma, this case demonstrates the effect of palliative chemotherapy in inactivating HPO in a rather short period of time.

Bone and Bones↗
PubMed1996

Radiotherapy for extreme hypertrophic pulmonary osteoarthropathy associated with malignancy.

A patient with florid hypertrophic pulmonary osteoarthropathy (HPOA) associated with metastatic nasopharyngeal carcinoma is presented. Despite the presence of metastatic disease in the thorax and in bone, the patient's main symptom was severe pain from the HPOA, which was temporarily relieved by chemotherapy. Her disease subsequently progressed during chemotherapy and the pain became resistant to conventional treatment, including high dose morphine, non-steriodal anti-inflammatory agents and steriods. It was only with local radiation to the involved joints that the pain could be controlled. Our patient demonstrates that local radiotherapy is an option for the palliation of extreme HPOA.

Adult↗